Serotype distribution of Streptococcus pneumoniae causing invasive disease in children in the post-PCV era: A

Evelyn Balsells1, Laurence Guillot1, Harish Nair1

  • 1Usher Institute of Population Health Sciences and Informatics, University of Edinburgh, Medical School, Teviot Place, Edinburgh, United Kingdom.

Plos One
|May 10, 2017
PubMed

Insights

Pneumococcal conjugate vaccines (PCV) reduced invasive pneumococcal disease (IPD). However, non-vaccine serotypes, particularly 19A, remain a concern post-PCV introduction, with significant regional variations. Continued surveillance is crucial.

Area of Science:

  • Microbiology
  • Vaccinology
  • Epidemiology

Background:

  • Routine immunization with pneumococcal conjugate vaccines (PCV7/10/13) has significantly reduced invasive pneumococcal disease (IPD) caused by vaccine serotypes.
  • An observed increase in IPD due to non-vaccine serotypes, known as serotype replacement, necessitates understanding individual serotype contributions.
  • Serotype distribution in children is critical for evaluating the overall impact of PCVs and guiding future vaccine development.

Purpose of the Study:

  • To examine the distribution of pneumococcal serotypes in children following the introduction of PCVs.
  • To identify the leading serotypes associated with childhood IPD in the post-PCV era.
  • To assess the impact of serotype replacement and regional variations in IPD epidemiology.

Main Methods:

  • Systematic literature search for studies and surveillance reports on childhood IPD serotypes (2000-2015).
  • Data differentiation based on vaccine type administered: PCV7 or higher valent PCVs (PCV10/PCV13).
  • Meta-analysis to estimate the proportional contributions of frequent serotypes in childhood IPD.

Main Results:

  • Serotype 19A was the predominant cause of IPD (21.8%) in the PCV7 era, with a lower contribution (14.2%) in the PCV10/PCV13 era.
  • Non-PCV13 serotypes accounted for 42.2% of childhood IPD cases, with significant regional variations (e.g., 71.9% in Europe, 9.2% in Eastern Mediterranean).
  • Key non-PCV13 serotypes included 22F, 12F, 33F, 24F, 15C, 15B, 23B, 10A, and 38, with regional rank order differences.

Conclusions:

  • Childhood IPD involves a diverse range of serotypes beyond those included in current vaccines.
  • Non-PCV13 serotypes represent a substantial proportion of IPD cases, particularly in the early years after higher valent PCV introduction.
  • Geographic diversity in serotype distribution underscores the need for ongoing surveillance to inform vaccine design and public health recommendations, especially in resource-limited settings.
Abstract

Related Concept Videos

Pneumonia II: Pathophysiology01:29

Pneumonia II: Pathophysiology

The pathophysiology of pneumonia involves the following steps:
3.6K
Pneumonia I: Introduction01:30

Pneumonia I: Introduction

Pneumonia is an acute respiratory infection that targets the lungs, specifically the alveoli. These tiny air sacs, essential for oxygen exchange, become engorged with pus and fluid, severely hindering breathing, decreasing oxygen absorption, and causing significant pain and discomfort during respiration.
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
1.1K
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
388
Pneumonia V: Nursing management and Prevention01:30

Pneumonia V: Nursing management and Prevention

Nursing management of pneumonia involves promoting airway patency, facilitating rest and conserving energy, encouraging fluid intake, maintaining nutrition, and educating patients.
The nurse must practice strict medical asepsis and adhere to infection control guidelines to minimize healthcare-associated infections.
Enhance airway patency
Position the patient correctly to facilitate drainage of the affected lung segments. Manual or mechanical percussion and vibration can also be employed....
3.7K
Pneumonia III: Complications and Assessment01:30

Pneumonia III: Complications and Assessment

Pneumonia poses the potential for numerous complications that warrant consideration. These complications include the following:
1.0K
Pneumonia IV: Management01:28

Pneumonia IV: Management

The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
944